A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.
Identifieur interne : 002910 ( PubMed/Curation ); précédent : 002909; suivant : 002911A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.
Auteurs : A Gabriella Wernicke [États-Unis] ; Robert L. Goodman ; Bruce C. Turner ; Lydia T. Komarnicky ; Walter J. Curran ; Paul J. Christos ; Imraan Khan ; Katherine Vandris ; Bhupesh Parashar ; Dattatreyudu Nori ; K S Clifford ChaoSource :
- Breast cancer research and treatment [ 1573-7217 ] ; 2011.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Aisselle (anatomopathologie), Facteurs temps, Femelle, Humains, Lymphadénectomie (effets indésirables), Métastase lymphatique, Noeuds lymphatiques (anatomopathologie), Radiothérapie (), Radiothérapie adjuvante (), Relation dose-effet des radiations, Région mammaire (anatomopathologie), Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs du sein (anatomopathologie), Tumeurs du sein (diagnostic), Tumeurs du sein (radiothérapie), Études de cohortes, Études de suivi.
- MESH :
- anatomopathologie : Aisselle, Noeuds lymphatiques, Région mammaire, Tumeurs du sein.
- diagnostic : Tumeurs du sein.
- effets indésirables : Lymphadénectomie.
- radiothérapie : Tumeurs du sein.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Métastase lymphatique, Radiothérapie, Radiothérapie adjuvante, Relation dose-effet des radiations, Résultat thérapeutique, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Études de cohortes, Études de suivi.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Axilla (pathology), Breast (pathology), Breast Neoplasms (diagnosis), Breast Neoplasms (pathology), Breast Neoplasms (radiotherapy), Cohort Studies, Disease-Free Survival, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Humans, Lymph Node Excision (adverse effects), Lymph Nodes (pathology), Lymphatic Metastasis, Middle Aged, Radiotherapy (methods), Radiotherapy, Adjuvant (methods), Time Factors, Treatment Outcome.
- MESH :
- adverse effects : Lymph Node Excision.
- diagnosis : Breast Neoplasms.
- methods : Radiotherapy, Radiotherapy, Adjuvant.
- pathology : Axilla, Breast, Breast Neoplasms, Lymph Nodes.
- radiotherapy : Breast Neoplasms.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Disease-Free Survival, Dose-Response Relationship, Radiation, Female, Follow-Up Studies, Humans, Lymphatic Metastasis, Middle Aged, Time Factors, Treatment Outcome.
Abstract
We compare long-term outcomes in patients with node negative early stage breast cancer treated with breast radiotherapy (RT) without the axillary RT field after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). We hypothesize that though tangential RT was delivered to the breast tissue, it at least partially sterilized occult axillary nodal metastases thus providing low nodal failure rates. Between 1995 and 2001, 265 patients with AJCC stages I-II breast cancer were treated with lumpectomy and either SLND (cohort SLND) or SLND and ALND (cohort ALND). Median follow-up was 9.9 years (range 8.3-15.3 years). RT was administered to the whole breast to the median dose of 48.2 Gy (range 46.0-50.4 Gy) plus boost without axillary RT. Chi-square tests were employed in comparing outcomes of two groups for axillary and supraclavicular failure rates, ipsilateral in-breast tumor recurrence (IBTR), distant metastases (DM), and chronic complications. Progression-free survival (PFS) was compared using log-rank test. There were 136/265 (51%) and 129/265 (49%) patients in the SLND and ALND cohorts, respectively. The median number of axillary lymph nodes assessed was 2 (range 1-5) in cohort SLND and 18 (range 7-36) in cohort ALND (P < 0.0001). Incidence of AFR and SFR in both cohorts was 0%. The rates of IBTR and DM in both cohorts were not significantly different. Median PFS in the SLND cohort is 14.6 years and 10-year PFS is 88.2%. Median PFS in the ALND group is 15.0 years and 10-year PFS is 85.7%. At a 10-year follow-up chronic lymphedema occurred in 5/108 (4.6%) and 40/115 (34.8%) in cohorts SLND and ALND, respectively (P = 0.0001). This study provides mature evidence that patients with negative nodes, treated with tangential breast RT and SLND alone, experience low AFR or SFR. Our findings, while awaiting mature long-term data from NSABP B-32, support that in patients with negative axillary nodal status such treatment provides excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.
DOI: 10.1007/s10549-010-1167-6
PubMed: 20853176
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002910
Links to Exploration step
pubmed:20853176Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.</title><author><name sortKey="Wernicke, A Gabriella" sort="Wernicke, A Gabriella" uniqKey="Wernicke A" first="A Gabriella" last="Wernicke">A Gabriella Wernicke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Stich Radiation Oncology, Weil Cornell Medical College of Cornell University, 525 East 68th Street, New York, NY 10065, USA. gaw9008@med.cornell.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Stich Radiation Oncology, Weil Cornell Medical College of Cornell University, 525 East 68th Street, New York, NY 10065</wicri:regionArea></affiliation></author><author><name sortKey="Goodman, Robert L" sort="Goodman, Robert L" uniqKey="Goodman R" first="Robert L" last="Goodman">Robert L. Goodman</name></author><author><name sortKey="Turner, Bruce C" sort="Turner, Bruce C" uniqKey="Turner B" first="Bruce C" last="Turner">Bruce C. Turner</name></author><author><name sortKey="Komarnicky, Lydia T" sort="Komarnicky, Lydia T" uniqKey="Komarnicky L" first="Lydia T" last="Komarnicky">Lydia T. Komarnicky</name></author><author><name sortKey="Curran, Walter J" sort="Curran, Walter J" uniqKey="Curran W" first="Walter J" last="Curran">Walter J. Curran</name></author><author><name sortKey="Christos, Paul J" sort="Christos, Paul J" uniqKey="Christos P" first="Paul J" last="Christos">Paul J. Christos</name></author><author><name sortKey="Khan, Imraan" sort="Khan, Imraan" uniqKey="Khan I" first="Imraan" last="Khan">Imraan Khan</name></author><author><name sortKey="Vandris, Katherine" sort="Vandris, Katherine" uniqKey="Vandris K" first="Katherine" last="Vandris">Katherine Vandris</name></author><author><name sortKey="Parashar, Bhupesh" sort="Parashar, Bhupesh" uniqKey="Parashar B" first="Bhupesh" last="Parashar">Bhupesh Parashar</name></author><author><name sortKey="Nori, Dattatreyudu" sort="Nori, Dattatreyudu" uniqKey="Nori D" first="Dattatreyudu" last="Nori">Dattatreyudu Nori</name></author><author><name sortKey="Chao, K S Clifford" sort="Chao, K S Clifford" uniqKey="Chao K" first="K S Clifford" last="Chao">K S Clifford Chao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:20853176</idno><idno type="pmid">20853176</idno><idno type="doi">10.1007/s10549-010-1167-6</idno><idno type="wicri:Area/PubMed/Corpus">002910</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002910</idno><idno type="wicri:Area/PubMed/Curation">002910</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002910</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.</title><author><name sortKey="Wernicke, A Gabriella" sort="Wernicke, A Gabriella" uniqKey="Wernicke A" first="A Gabriella" last="Wernicke">A Gabriella Wernicke</name><affiliation wicri:level="1"><nlm:affiliation>Department of Radiation Oncology, Stich Radiation Oncology, Weil Cornell Medical College of Cornell University, 525 East 68th Street, New York, NY 10065, USA. gaw9008@med.cornell.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Radiation Oncology, Stich Radiation Oncology, Weil Cornell Medical College of Cornell University, 525 East 68th Street, New York, NY 10065</wicri:regionArea></affiliation></author><author><name sortKey="Goodman, Robert L" sort="Goodman, Robert L" uniqKey="Goodman R" first="Robert L" last="Goodman">Robert L. Goodman</name></author><author><name sortKey="Turner, Bruce C" sort="Turner, Bruce C" uniqKey="Turner B" first="Bruce C" last="Turner">Bruce C. Turner</name></author><author><name sortKey="Komarnicky, Lydia T" sort="Komarnicky, Lydia T" uniqKey="Komarnicky L" first="Lydia T" last="Komarnicky">Lydia T. Komarnicky</name></author><author><name sortKey="Curran, Walter J" sort="Curran, Walter J" uniqKey="Curran W" first="Walter J" last="Curran">Walter J. Curran</name></author><author><name sortKey="Christos, Paul J" sort="Christos, Paul J" uniqKey="Christos P" first="Paul J" last="Christos">Paul J. Christos</name></author><author><name sortKey="Khan, Imraan" sort="Khan, Imraan" uniqKey="Khan I" first="Imraan" last="Khan">Imraan Khan</name></author><author><name sortKey="Vandris, Katherine" sort="Vandris, Katherine" uniqKey="Vandris K" first="Katherine" last="Vandris">Katherine Vandris</name></author><author><name sortKey="Parashar, Bhupesh" sort="Parashar, Bhupesh" uniqKey="Parashar B" first="Bhupesh" last="Parashar">Bhupesh Parashar</name></author><author><name sortKey="Nori, Dattatreyudu" sort="Nori, Dattatreyudu" uniqKey="Nori D" first="Dattatreyudu" last="Nori">Dattatreyudu Nori</name></author><author><name sortKey="Chao, K S Clifford" sort="Chao, K S Clifford" uniqKey="Chao K" first="K S Clifford" last="Chao">K S Clifford Chao</name></author></analytic><series><title level="j">Breast cancer research and treatment</title><idno type="eISSN">1573-7217</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Axilla (pathology)</term><term>Breast (pathology)</term><term>Breast Neoplasms (diagnosis)</term><term>Breast Neoplasms (pathology)</term><term>Breast Neoplasms (radiotherapy)</term><term>Cohort Studies</term><term>Disease-Free Survival</term><term>Dose-Response Relationship, Radiation</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymph Node Excision (adverse effects)</term><term>Lymph Nodes (pathology)</term><term>Lymphatic Metastasis</term><term>Middle Aged</term><term>Radiotherapy (methods)</term><term>Radiotherapy, Adjuvant (methods)</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Aisselle (anatomopathologie)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie (effets indésirables)</term><term>Métastase lymphatique</term><term>Noeuds lymphatiques (anatomopathologie)</term><term>Radiothérapie ()</term><term>Radiothérapie adjuvante ()</term><term>Relation dose-effet des radiations</term><term>Région mammaire (anatomopathologie)</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs du sein (anatomopathologie)</term><term>Tumeurs du sein (diagnostic)</term><term>Tumeurs du sein (radiothérapie)</term><term>Études de cohortes</term><term>Études de suivi</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Aisselle</term><term>Noeuds lymphatiques</term><term>Région mammaire</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Lymphadénectomie</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiotherapy</term><term>Radiotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Axilla</term><term>Breast</term><term>Breast Neoplasms</term><term>Lymph Nodes</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Disease-Free Survival</term><term>Dose-Response Relationship, Radiation</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lymphatic Metastasis</term><term>Middle Aged</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Métastase lymphatique</term><term>Radiothérapie</term><term>Radiothérapie adjuvante</term><term>Relation dose-effet des radiations</term><term>Résultat thérapeutique</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Études de cohortes</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compare long-term outcomes in patients with node negative early stage breast cancer treated with breast radiotherapy (RT) without the axillary RT field after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). We hypothesize that though tangential RT was delivered to the breast tissue, it at least partially sterilized occult axillary nodal metastases thus providing low nodal failure rates. Between 1995 and 2001, 265 patients with AJCC stages I-II breast cancer were treated with lumpectomy and either SLND (cohort SLND) or SLND and ALND (cohort ALND). Median follow-up was 9.9 years (range 8.3-15.3 years). RT was administered to the whole breast to the median dose of 48.2 Gy (range 46.0-50.4 Gy) plus boost without axillary RT. Chi-square tests were employed in comparing outcomes of two groups for axillary and supraclavicular failure rates, ipsilateral in-breast tumor recurrence (IBTR), distant metastases (DM), and chronic complications. Progression-free survival (PFS) was compared using log-rank test. There were 136/265 (51%) and 129/265 (49%) patients in the SLND and ALND cohorts, respectively. The median number of axillary lymph nodes assessed was 2 (range 1-5) in cohort SLND and 18 (range 7-36) in cohort ALND (P < 0.0001). Incidence of AFR and SFR in both cohorts was 0%. The rates of IBTR and DM in both cohorts were not significantly different. Median PFS in the SLND cohort is 14.6 years and 10-year PFS is 88.2%. Median PFS in the ALND group is 15.0 years and 10-year PFS is 85.7%. At a 10-year follow-up chronic lymphedema occurred in 5/108 (4.6%) and 40/115 (34.8%) in cohorts SLND and ALND, respectively (P = 0.0001). This study provides mature evidence that patients with negative nodes, treated with tangential breast RT and SLND alone, experience low AFR or SFR. Our findings, while awaiting mature long-term data from NSABP B-32, support that in patients with negative axillary nodal status such treatment provides excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20853176</PMID><DateCreated><Year>2011</Year><Month>01</Month><Day>20</Day></DateCreated><DateCompleted><Year>2011</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7217</ISSN><JournalIssue CitedMedium="Internet"><Volume>125</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Breast cancer research and treatment</Title><ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation></Journal><ArticleTitle>A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.</ArticleTitle><Pagination><MedlinePgn>893-902</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-010-1167-6</ELocationID><Abstract><AbstractText>We compare long-term outcomes in patients with node negative early stage breast cancer treated with breast radiotherapy (RT) without the axillary RT field after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). We hypothesize that though tangential RT was delivered to the breast tissue, it at least partially sterilized occult axillary nodal metastases thus providing low nodal failure rates. Between 1995 and 2001, 265 patients with AJCC stages I-II breast cancer were treated with lumpectomy and either SLND (cohort SLND) or SLND and ALND (cohort ALND). Median follow-up was 9.9 years (range 8.3-15.3 years). RT was administered to the whole breast to the median dose of 48.2 Gy (range 46.0-50.4 Gy) plus boost without axillary RT. Chi-square tests were employed in comparing outcomes of two groups for axillary and supraclavicular failure rates, ipsilateral in-breast tumor recurrence (IBTR), distant metastases (DM), and chronic complications. Progression-free survival (PFS) was compared using log-rank test. There were 136/265 (51%) and 129/265 (49%) patients in the SLND and ALND cohorts, respectively. The median number of axillary lymph nodes assessed was 2 (range 1-5) in cohort SLND and 18 (range 7-36) in cohort ALND (P < 0.0001). Incidence of AFR and SFR in both cohorts was 0%. The rates of IBTR and DM in both cohorts were not significantly different. Median PFS in the SLND cohort is 14.6 years and 10-year PFS is 88.2%. Median PFS in the ALND group is 15.0 years and 10-year PFS is 85.7%. At a 10-year follow-up chronic lymphedema occurred in 5/108 (4.6%) and 40/115 (34.8%) in cohorts SLND and ALND, respectively (P = 0.0001). This study provides mature evidence that patients with negative nodes, treated with tangential breast RT and SLND alone, experience low AFR or SFR. Our findings, while awaiting mature long-term data from NSABP B-32, support that in patients with negative axillary nodal status such treatment provides excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wernicke</LastName><ForeName>A Gabriella</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Stich Radiation Oncology, Weil Cornell Medical College of Cornell University, 525 East 68th Street, New York, NY 10065, USA. gaw9008@med.cornell.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodman</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Bruce C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Komarnicky</LastName><ForeName>Lydia T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>Walter J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Christos</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Imraan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Vandris</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Parashar</LastName><ForeName>Bhupesh</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nori</LastName><ForeName>Dattatreyudu</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>K S Clifford</ForeName><Initials>KS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 RR024996</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-RR024996</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Breast Cancer Res Treat</MedlineTA><NlmUniqueID>8111104</NlmUniqueID><ISSNLinking>0167-6806</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2010 Apr;251(4):595-600</RefSource><PMID Version="1">20195151</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2009 May;45(8):1381-8</RefSource><PMID Version="1">19128957</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Sep 1;28(25):3929-36</RefSource><PMID Version="1">20679600</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):815-22</RefSource><PMID Version="1">10705001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):327-33</RefSource><PMID Version="1">10802356</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):99-105</RefSource><PMID Version="1">11316551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):69-73</RefSource><PMID Version="1">11516853</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):671-8</RefSource><PMID Version="1">11597808</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Aug 22;347(8):567-75</RefSource><PMID Version="1">12192016</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2002 Oct 17;347(16):1233-41</RefSource><PMID Version="1">12393820</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8</RefSource><PMID Version="1">12629218</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2003 Aug 7;349(6):546-53</RefSource><PMID Version="1">12904519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1280-8</RefSource><PMID Version="1">15001273</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1575-82</RefSource><PMID Version="1">3759582</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1989 Jan 1;63(1):181-7</RefSource><PMID Version="1">2910416</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Oncol (R Coll Radiol). 1993;5(5):278-83</RefSource><PMID Version="1">8305334</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Surg Oncol. 1993 Dec;2(6):335-9; discussion 340</RefSource><PMID Version="1">8130940</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Histopathology. 1994 Jan;24(1):41-7</RefSource><PMID Version="1">8144141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401</RefSource><PMID Version="1">8092905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 1995 Jan 4;87(1):19-27</RefSource><PMID Version="1">7666458</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1995 Nov 1;76(9):1491-512</RefSource><PMID Version="1">8635050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1996 Dec 11;276(22):1818-22</RefSource><PMID Version="1">8946902</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1997 Jun 28;349(9069):1864-7</RefSource><PMID Version="1">9217757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):915-20</RefSource><PMID Version="1">9369141</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2776-81</RefSource><PMID Version="1">9874397</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Radiology. 1999 Jan;210(1):221-6</RefSource><PMID Version="1">9885612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 1999 Jan-Feb;6(1):109-16</RefSource><PMID Version="1">10030423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 1999 Jul 17;354(9174):197-202</RefSource><PMID Version="1">10421301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1955 Jul-Aug;8(4):776-8</RefSource><PMID Version="1">13240660</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2005 Jan;241(1):48-54</RefSource><PMID Version="1">15621990</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2005 Jan;41(2):231-7</RefSource><PMID Version="1">15661547</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Radiol. 2005 Jan;78(925):51-4</RefSource><PMID Version="1">15673530</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2005 Mar;16(3):383-8</RefSource><PMID Version="1">15668261</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2005 Dec 17;366(9503):2087-106</RefSource><PMID Version="1">16360786</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2006 Feb;42(3):351-6</RefSource><PMID Version="1">16314086</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2006 May 3;98(9):599-609</RefSource><PMID Version="1">16670385</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Chir. 2006 Dec;131(10):608-15</RefSource><PMID Version="1">16884676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 2007 May;119(6):1813-22</RefSource><PMID Version="1">17440362</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Aug 20;25(24):3657-63</RefSource><PMID Version="1">17485711</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2007 Oct;8(10):881-8</RefSource><PMID Version="1">17851130</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Jan;15(1):262-7</RefSource><PMID Version="1">17879117</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg. 2008 Feb;247(2):207-13</RefSource><PMID Version="1">18216523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Surg Oncol. 2008 Mar;15(3):863-71</RefSource><PMID Version="1">18043970</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1468-71</RefSource><PMID Version="1">17967511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Jul 20;26(21):3530-5</RefSource><PMID Version="1">18640934</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):866-70</RefSource><PMID Version="1">18394815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):80-7</RefSource><PMID Version="1">18602764</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Surg Oncol. 2010 Aug 1;102(2):111-8</RefSource><PMID Version="1">20648579</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001365" MajorTopicYN="N">Axilla</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001940" MajorTopicYN="N">Breast</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004307" MajorTopicYN="N">Dose-Response Relationship, Radiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011878" MajorTopicYN="N">Radiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018714" MajorTopicYN="N">Radiotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS452458</OtherID><OtherID Source="NLM">PMC3623372</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>08</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20853176</ArticleId><ArticleId IdType="doi">10.1007/s10549-010-1167-6</ArticleId><ArticleId IdType="pmc">PMC3623372</ArticleId><ArticleId IdType="mid">NIHMS452458</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002910 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002910 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:20853176
|texte= A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:20853176" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |